Coverage
-
October 05, 2015
A Massachusetts federal judge on Monday divvied out more than $8 million in expenses for a settlement reached between Nexium buyers and Teva Pharmaceutical Industries Ltd., but agreed to hold off on approving fees for AstraZeneca PLC and Ranbaxy Inc. following their win in a multidistrict litigation pay-for-delay trial brought by the same buyers.
49 other articles on this case.
View all »